1. Home
  2. BLIN vs PHIO Comparison

BLIN vs PHIO Comparison

Compare BLIN & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgeline Digital Inc.

BLIN

Bridgeline Digital Inc.

N/A

Current Price

$0.85

Market Cap

12.1M

Sector

Technology

ML Signal

N/A

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

N/A

Current Price

$1.00

Market Cap

12.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLIN
PHIO
Founded
2000
2003
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
12.9M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
BLIN
PHIO
Price
$0.85
$1.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$4.62
★ $14.00
AVG Volume (30 Days)
27.9K
★ 131.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $13,568,000.00
N/A
Revenue This Year
$22.67
N/A
Revenue Next Year
$21.08
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.69
$0.81
52 Week High
$1.59
$4.19

Technical Indicators

Market Signals
Indicator
BLIN
PHIO
Relative Strength Index (RSI) 29.50 46.32
Support Level $0.82 $0.98
Resistance Level $0.87 $1.12
Average True Range (ATR) 0.05 0.05
MACD 0.00 -0.00
Stochastic Oscillator 21.36 50.88

Price Performance

Historical Comparison
BLIN
PHIO

About BLIN Bridgeline Digital Inc.

Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: